Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, May 7, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Fri, May 4, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Stephen Willey Maintained (ALNY) at Hold with Decreased Target to $95 on, May 4th, 2018
Stephen Willey of Stifel, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Hold with Decreased Target from $107 to $95 on, May 4th, 2018.
Stephen has made no other calls on ALNY in the last 4 months.
There are 3 other peers that have a rating on ALNY. Out of the 3 peers that are also analyzing ALNY, 2 agree with Stephen's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- David Lebovitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $118 on, Friday, February 9th, 2018
- Paul Matteis of "Leerink Swann" Maintained at Hold with Increased Target to $135 on, Thursday, January 25th, 2018
This is the rating of the analyst that currently disagrees with Stephen
- Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $154 on, Tuesday, March 13th, 2018
